| Index | — | P/E | — | EPS (ttm) | — | Insider Own | — | Shs Outstand | 129.64M | Perf Week | -4.86% |
| Market Cap | 1.58B | Forward P/E | — | EPS next Y | -4.30 | Insider Trans | 0.00% | Shs Float | 89.39M | Perf Month | 16.94% |
| Enterprise Value | 668.17M | PEG | — | EPS next Q | -1.01 | Short Float | 9.30% | Perf Quarter | -32.91% | ||
| Income | -149.00M | P/S | — | EPS this Y | — | Short Ratio | 8.78 | Perf Half Y | -51.57% | ||
| Sales | 0.00 | P/B | 1.41 | EPS next Y | — | ROA | -15.70% | Short Interest | 8.32M | Perf YTD | -53.27% |
| Book/sh | 8.62 | P/C | 1.72 | EPS next 5Y | — | ROE | -55.41% | 52W High | 28.23 -56.96% | Perf Year | — |
| Cash/sh | 7.07 | P/FCF | — | EPS past 3/5Y | — | ROIC | -18.25% | 52W Low | 9.76 24.49% | Perf 3Y | — |
| Dividend Est. | — | EV/EBITDA | — | Sales past 3/5Y | — | Gross Margin | 0.00% | Volatility | 6.09% 7.32% | Perf 5Y | — |
| Dividend TTM | — | EV/Sales | — | EPS Y/Y TTM | — | Oper. Margin | 0.00% | ATR (14) | 0.87 | Perf 10Y | — |
| Dividend Ex-Date | — | Quick Ratio | 11.11 | Sales Y/Y TTM | — | Profit Margin | 0.00% | RSI (14) | 46.61 | Recom | 2.00 |
| Dividend Gr. 3/5Y | — | Current Ratio | 11.11 | EPS Q/Q | 99.97% | SMA20 | 1.30% | Beta | 1.20 | Target Price | 42.00 |
| Payout | 0.00% | Debt/Eq | 0.01 | Sales Q/Q | — | SMA50 | -7.90% | Rel Volume | 0.84 | Prev Close | 12.86 |
| Employees | 145 | LT Debt/Eq | 0.01 | Earnings | Dec 02 | SMA200 | -32.25% | Avg Volume | 1.05M | Price | 12.15 |
| IPO Date | Apr 17, 2026 | Option/Short | No / Yes | EPS/Sales Surpr. | -28.49% — | Net Debt/EBITDA | — | Volume | 881,420 | Change | -5.52% |
| Date | Action | Analyst | Rating | Target |
|---|---|---|---|---|
| May-12-26 | Initiated | Leerink | Outperform | $36 |
| May-12-26 | Initiated | Jefferies | Buy | $48 |
Kailera Therapeutics, Inc. operates as a clinical-stage biopharmaceutical company developing therapies for obesity and related conditions. The company develops clinical- and preclinical-stage therapies, with a product pipeline that includes injectable peptides, oral peptides, and oral small molecules. Key programs include KAI-9531, an injectable GLP-1/GIP receptor dual agonist; KAI-7535, an oral small molecule GLP-1 receptor agonist; and KAI-4729, an injectable GLP-1/GIP/glucagon receptor tri-agonist. Kailera Therapeutics holds exclusive rights for global development and commercialization of four metabolic disease assets outside of Greater China, with therapies delivered through oral and injectable formulations. The company was founded in 2024 and is based in Waltham, Massachusetts.
Per-holder 13F data hasn't been ingested for this ticker yet.
| Line Item (USD, M) | FY 2025 12/31/2025 | |
|---|---|---|
| Total Revenue | 0 | |
| Cost of Goods Sold Incl. D&A | 0 | |
| Gross Profit | 0 | |
| Selling, General and Administrative Excl. Other | 49 | |
| Research and Development | 109 | |
| Other Operating Expense | 0 | |
| Operating Income | -158 | |
| Interest Expense | 0 | |
| Unusual Expense | — | |
| Non-Operating Income (Expense) | 9 | |
| Net Income Before Taxes | -149 | |
| Income Taxes | 0 | |
| Consolidated Net Income | -149 | |
| Net Income From Continuing Operations | -149 | |
| Net Income | -149 | |
| EPS (Recurring) | -1.26 | |
| EPS (Basic, Before Extraordinaries) | -1.26 | |
| EPS (Diluted) | -1.26 | |
| EBITDA | -158 | |
| Other After Tax Adjustments | — | |
| Stock Option Compensation Expense | — | |
| Price To Earnings Ratio | — | |
| Price To Sales Ratio | — | |
| Gross Margin | — | |
| Operating Margin | — | |
| Net Margin | — | |
| Shares Outstanding | 118 | |
| Market Capitalization | — | |
| Operating Lease Expense | — |
| Insider | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total | SEC Form 4 |
|---|---|---|---|---|---|---|---|---|
| Renaud Ronald C JR | CEO & President | Jun 09 '26 | Option Exercise | 5.25 | 38,094 | 199,994 | 38,094 | Jun 11 |
| RTW INVESTMENTS, LP | 10% Owner | Apr 20 '26 | Buy | 16.00 | 500,000 | 8,000,000 | 10,776,820 | Apr 22 |
| Bain Capital Life Sciences Investors, LLC | 10% Owner | Apr 20 '26 | Buy | 16.00 | 1,562,500 | 25,000,000 | 22,583,268 | Apr 20 |
| BAIN CAPITAL INVESTORS LLC | 10% Owner | Apr 20 '26 | Buy | 16.00 | 8,398,438 | 134,375,008 | 26,255,581 | Apr 20 |
| Koppel Adam | Director, 10% Owner | Apr 20 '26 | Buy | 16.00 | 1,562,500 | 25,000,000 | 22,583,268 | Apr 20 |
| Kaplan Andrew T. | Director, 10% Owner | Apr 20 '26 | Buy | 16.00 | 8,398,438 | 134,375,008 | 26,255,581 | Apr 20 |